Conclusions

In the final segment, the panelists bring together the major insights from across the series, highlighting the most clinically meaningful data from monarchE, NATALEE, and VIKTORIA-1 and what these findings mean for the evolving role of CDK4/6 inhibitors in both early-stage and metastatic HR+ breast cancer. They outline key takeaways for pharmacists and care teams—from interpreting long-term survival signals to integrating emerging biomarker data and preparing for new combination strategies on the horizon. The discussion closes with a forward-looking perspective on what’s next in this rapidly advancing space, including anticipated updates, ongoing trials, and the growing importance of personalized, mechanism-driven treatment approaches.